recombinant)
Sponsors
Centre hospitalier universitaire de Liege, Gentofte Hospital, Pfizer Inc., Region Skane, Centre Hospitalier Annecy Genevois, Fondazione Penta Ets
Conditions
BronchiolitisInflammatory rheumatic diseasePrevention of lower respiratory tract disease caused by respiratory syncytial virusRSV-infectionRespiratory Syncytial Virus (RSV)Respiratory syncytial virus infectionRespiratory tract infectionallogeneic - Hematopoietic Stem Cell Transplantation
Phase 2
A Phase II randomized trial of RSV vaccination in allogeneic hematopoietic stem cell transplant recipients (RSV-Allo study)
RecruitingCTIS2024-513290-53-00
Start: 2024-11-07Target: 204Updated: 2025-05-05
Immunogenicity and safety of two respiratory syncytial virus vaccine strategies in lung and allogeneic haematopoietic stem cell transplant recipients: A phase 2 trial
RSVaxID
Not yet recruitingCTIS2025-524374-42-00
Target: 400Updated: 2026-07-06
Phase 3
Prevention of RSV infection in infants by administering nirsevimab to infants, with or without maternal RSV vaccination: a randomised controlled trial in France as part of the Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)
Not yet recruitingCTIS2025-521755-23-00
Target: 2000Updated: 2025-10-21
Pregnancy and Infant PrEparedness pLatform IN Europe (PIPELINE)-RSV immunisation adaptive platform trial
Not yet recruitingCTIS2025-522194-11-00
Target: 400Updated: 2025-11-04
C3671017 A PHASE 3 STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND IMMUNOGENICITY OF A RESPIRATORY SYNCYTIAL VIRUS VACCINE IN CHILDREN AT HIGH RISK OF RSV DISEASE
Not yet recruitingCTIS2026-525797-19-00
Target: 460Updated: 2026-10-02
Phase 4
A Pragmatic Randomized Trial to Evaluate the Vaccine Effectiveness of Abrysvo® for Preventing RSV Hospitalizations in Adults Aged 18 Years or Above (DAN-RSV)
RecruitingCTIS2024-516600-42-00
Start: 2024-11-18Target: 890000Updated: 2025-11-03
Vaccination against respiratory syncytial virus in patients with inflammatory rheumatic diseases. The impact of anti-rheumatic treatments on the RSV immune response.
Not yet recruitingCTIS2024-518191-31-00
Target: 180Updated: 2025-07-09
A Pragmatic Randomized Trial to Evaluate the Relative Effectiveness of Abrysvo® Revaccination Versus a Single Primary Dose for Preventing RSV-associated Lower Respiratory Tract Disease in Immunocompromised Adults (DAN-RSV IC REVAX)
Not yet recruitingCTIS2026-527536-14-00
Target: 29000Updated: 2026-09-21